Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective is to compare weight gain (g/day) of infants receiving new protein fortifier (PF) according to a blood urea nitrogen (BUN)-driven fortification regimen to weight gain (g/day) of infants receiving PF according to a weight-driven fortification regimen (standard of care) over a 21 day period.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Weight-driven protein fortification | Active Comparator | Individualized protein fortification based on weight gain |
|
| BUN-driven protein fortification | Experimental | Individualized protein fortification based on BUN concentrations |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Protein fortifier | Combination Product | Protein Fortifier to be added to Fortified human milk according to feeding regimen |
|
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of weight gain | To compare weight gain (g/day) of infants receiving new protein fortifier (PF) according to a BUN-driven fortification regimen to weight gain (g/day) of infants receiving PF according to a weight-driven fortification regimen | From Day 6 to Day 27 |
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of weight gain (g/day) of infants after 1 and 3 weeks of individualized protein fortification to weight gain during the 5-day period of standard Human Milk (HM) fortification | Comparison of weight gain (g/day) of infants after 1 and 3 weeks of individualized protein fortification to weight gain during the 5-day period of standard HM fortification | Day 6 to Day 13, and Day 6 to Day 27 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Infants with weight z-score < -2 SD, based on the Fenton growth chart (Fenton 2013)
Intra-ventricular hemorrhage (grade 3-4) determined using cranial ultrasonography or periventricular leukomalacia.
Renal disease determined by symptoms (oliguria, anuria, proteinuria, hematuria) associated with an increased creatinine.
Cholestasis (total bilirubin > 5 mg/dL or 85 umol/L and direct bilirubin > 20% of total bilirubin) associated with one or more abnormal liver function tests (AST, ALT, or GGT).
Major congenital malformations that may impact ability to accept enteral feedings (i.e., severe cleft palate, etc.).
Suspected or documented systemic or congenital infections (i.e., human immunodeficiency virus, cytomegalovirus, etc.).
Evidence of cardiac, respiratory, endocrinologic, hematologic, gastrointestinal, or other systemic diseases that may impact growth, e.g.,:
Suspected or documented maternal substance abuse:
Subjects' parent(s) or legal representative who are not willing and not able to comply with scheduled visits and the requirements of the study protocol
Infants who have received any experimental treatment or received any other investigational intervention (procedure or product) unrelated to this trial, prior to enrollment
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sebastien Paoli, Msc | Nestlé Research | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hopital de la Croix Rousse | Lyon | 69004 | France |
Not provided
| ID | Term |
|---|---|
| D015430 | Weight Gain |
| ID | Term |
|---|---|
| D001836 | Body Weight Changes |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Changes in growth parameters: Lengths (crown-heel and knee-heel) and length gain (cm) | Changes in growth parameters: Lengths (crown-heel and knee-heel) and length gain (cm) | Day 6 to Day 27 (minimum) |
| Changes in growth parameters: head circumference and head circumference gain (cm) | Changes in growth parameters: head circumference and head circumference gain (cm) | Day 6 to Day 27 (minimum) |
| Changes in growth parameters: BMI and BMI changes (kg body weight/m^2) | Changes in growth parameters: BMI and BMI changes (kg body weight/m^2) | Day 6 to Day 27 (minimum) |
| Body composition including lean fat mass and fat-free mass | Body composition including lean fat mass and fat-free mass | Day 6 to Day 27 (minimum) |
| Weight at hospital discharge | Weight at hospital discharge | Day 27 (minimum) |
| Macronutrient content in human milk | Macronutrient content in human milk using a Miris Human Milk Analyzer to measure the composition of the human milk | Day 6 to Day 27 (minimum) |
| Feeding and gastrointestinal (GI) tolerance | Feeding and gastrointestinal (GI) tolerance determined using Digestive tolerance scores based on four binary parameters (0 = absence or 1 = presence) collected in daily routine care: Sore abdomen, liquid stools, gastric residuals, and regurgitation or vomiting | Day 6 to Day 27 (minimum) |
| Safety evaluation including number of subjects with AEs | Safety evaluation including number of subjects with AEs | Day 1 to Day 27 (minimum) |
| Biochemistry markers collected from blood and urine as part of routine NICU standard of care | Biochemistry markers collected from blood and urine as part of routine NICU standard of care: Routine biochemistries in Blood/Serum and Urine (in spot urine samples), and Nutrition markers in Blood/serum: albumin, pre-albumin, alkaline phosphatase, triglycerides and vitamin D | Day 6 to Day 27 (minimum) |